ADIENNE Pharma & Biotech has signed a service agreement with Selexis for the development of a manufacturing cell line for one of the ADIENNE’s orphan drugs.
Selexis CEO Igor Fisch said, “Combining our expertise in difficult-to-express proteins with our SUREtechnology Platform(TM) is an important step in advancing ADIENNE’s project to the clinic.”
ADIENNE Pharma & Biotech founder and CEO Antonio Francesco Di Naro said Selexis expertise will be an added value for the company’s molecule.
Selexis is a global life sciences company for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins.
